CClinicalTrials.gg
TerminatedNCT04241419Updated Oct 23, 2024

A Pilot Study of High Intensity Walking in Older Adults in the Pre-operative Period

An interventional study of High Intensity Walking in Frailty, sponsored by University of Chicago. Terminated at 1 site in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2024-10-23.

Sponsored by University of Chicago · Not applicable, Interventional, and Prevention

Why this study was terminated
Unaware that the devices being used had a shelf life of only 6 months, the physical therapist could no longer assist with the study and did not have anyone to run the physical therapy aspect of the program.

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled May 2019, registered Jan 2020).
Phase
Not applicable
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
60 Years and older
Sex
All
01

Study summary

The purpose of this pilot study is to evaluate a high intensity walking intervention in older surgical candidates with kidney or thoracic disease and pre-frailty or frailty.

Read the detailed description

As the population ages, there are an increasing number of older adults presenting for surgical evaluation. Frailty evaluation has been recognized as a valuable tool in the pre-operative assessment of older adults. Frailty is a clinical syndrome with multiple causes and contributors that involves poor regulation of multiple physiologic systems and is characterized by reduced strength, endurance, and physiologic function. Frailty is a predictor of poor surgical outcomes in older patients, including post-operative complications, increased length of stay, post-discharge institutionalization, and mortality.Identification of frailty in the pre-operative period can aid in risk assessment and decision making for the procedure, can help inform a plan for post-operative care needs, and may provide a target for pre-operative risk reduction interventions.

Given the association of frailty with poor surgical outcomes and the high prevalence of frailty in surgical candidates, there has been much interest in interventions to mitigate this risk. Exercise interventions in other populations have shown success, although the optimal interventions are unknown. In both thoracic surgery and kidney transplantation, there may be a limited amount of time for intervention prior to the operation and patients often have other commitments, such as frequent medical appointments or dialysis sessions. Thus, a short duration program may be beneficial for these populations. High intensity walking is an approach that has shown to lead to functional gains in as short as 12 sessions. The therapists can also modify a high intensity walking program as needed for patients based on physical limitations, making it widely applicable for frail older adults of varying physical function levels, which is important to our older surgical populations. Surgical patients, which include kidney transplant and thoracic surgery patients, are particularly well suited to a pilot high intensity walking intervention given the high proportion of frailty and pre-frailty in these groups.

In this study, the investigator will examine a 12-week high intensity walking program for frail older surgical candidates.

02

Conditions studied

  • Frailty

Browse trials for

Keywords

  • ESRD
  • Thoracic Disease
  • Kidney Transplant
03

In context

Frailty

1,199 studies on the registry are indexed under Frailty; 430 are open to participants now.

This study's enrollment of 7 is below the median of 80 across 681 interventional studies indexed under Frailty.

Browse Frailty studies →

Lead sponsor

University of Chicago is the lead sponsor of 907 studies on the registry; 182 are open to participants now.

Of its 99 completed or terminated interventional studies of FDA-regulated products, 68 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 60 years of age or older
  • Provision of informed consent
  • No obvious contraindication to surgery such as uncontrolled cardiovascular, metabolic, or respiratory disease
  • Have either thoracic disease that may require major surgery or End-Stage Renal Disease or Chronic Kidney Disease under consideration for kidney transplant. The kidney transplant patients enrolled must be either a candidate for living donor transplantation or on the expedited deceased donor kidney transplant list, which indicates they are expected to receive an offer in approximately the next 3-5 months.
  • Able to ambulate at least 10 feet with moderate assistance (\<50% physical assistance)
  • Pre-frail or frail on the FRAIL screening tool (1+ positive on this tool)

Exclusion criteria

Exclusion Criteria:

  • Surgery planned within the 8 week study timeframe
  • Uncontrolled cardiovascular, metabolic, or respiratory disease that limits exercise participation
  • Resting blood pressure >180/110
  • Any pre-existing health condition that would make the subject a poor candidate for this study in the opinion of the PI
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    High Intensity Walking

    Participants will then undergo a 12 session intervention, with two sessions scheduled per week for six weeks. These will be 45 minute sessions, including 15 minutes of a warm-up and cool-down period as well as 30 minutes of walking. The intervention will include various types of over ground walking and stair work.

    Behavioral: High Intensity Walking

Interventions

  • BehavioralHigh Intensity Walking

    Participants will then undergo a 12 session intervention, with two sessions scheduled per week for six weeks. These will be 45 minute sessions, including 15 minutes of a warm-up and cool-down period as well as 30 minutes of walking. The intervention will include various types of over ground walking and stair work.

06

What researchers measure

Primary outcomes

  1. Phenotypic Frailty Criteria

    The phenotypic frailty criteria is a validated frailty measurement tool. Phenotypic frailty is a composite that includes grip strength measured via a dynamometer, self-reported weight loss, self-reported exhaustion using a validated two question screen, 15 foot gait speed, and activity level measured by the Minnesota Leisure Time Physical Activity Questionnaire. This will be measured at baseline and 8 weeks.

    Time frame: 8 weeks

Secondary outcomes

  1. Short Physical Performance Battery (SPPB)

    The SPPB is a mobility assessment which includes gait speed, sit to stand testing, and balance assessment. This will be measured at baseline and 8 weeks.

    Time frame: 8 weeks

  2. Berg Balance Scale

    The Berg balance scale will be used to assess the subject's balance at baseline and 8 weeks.

    Time frame: 8 weeks

  3. 6 minute walk test

    The distance a subject can walk in 6 minutes will be measured at baseline and 8 weeks.

    Time frame: 8 weeks

  4. PROMIS Global Health

    The PROMIS Global Health tool measures patient reported physical, mental, and social health, pain, and quality of life. This will be measured at baseline and 8 weeks.

    Time frame: 8 weeks

07

Study locations

1 site
  • The University of Chicago
    Chicago, Illinois 60637, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04241419
Lead sponsor
University of Chicago
Responsible party
Sponsor
First posted
Jan 27, 2020
Start date
May 15, 2019
Primary completion
Sep 6, 2023
Completion
Sep 6, 2023
Last update
Oct 23, 2024

Study contacts

Maria L Madariaga, MD
principal investigator · University of Chicago

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion